Non-Regulatory

February 10, 2021

Affibody and Inmagene announce IND Clearance for Izokibep (ABY-035) for the treatment of Ankylosing Spondylitis

Partners eye additional applications in autoimmune diseases during 2021 San Diego, U.S., Shanghai, China, and Solna, Sweden, February 10, 2021. Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced that...

Read more

Non-Regulatory

November 13, 2020

Interim Report – January to September 2020

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

November 10, 2020

Affibody Announces Initiation of Confirmatory Phase 2 Trial of ABY-035 in Psoriatic Arthritis Patients

Solna, Sweden, November 10, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced the initiation of its 52-week trial investigating the novel bispecific IL-17A inhibitor ABY-035 in...

Read more

Non-Regulatory

August 21, 2020

Interim Report – January to June 2020

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today...

Read more

Non-Regulatory

June 15, 2020

Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis

Solna, Sweden, June 15, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced positive top-line data from its 52-week trial investigating the novel bispecific IL-17A inhibitor ABY-035...

Read more

Non-Regulatory

June 15, 2020

Affibody Announces Termination of ABY-039 (FcRn) Program

Solna, Sweden, June 15, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company today announced the completion of its adaptive, double-blind, placebo-controlled Phase 1 study investigating safety, tolerability, pharmacokinetics,...

Read more

Non-Regulatory

May 25, 2020

Notice to attend Annual General Meeting

The shareholders of Affibody Medical AB are hereby invited to attend the annual general meeting of the shareholders on Tuesday 23 June 2020, at 2 pm, to be held...

Read more

Non-Regulatory

May 15, 2020

Interim Report – January to March 2020

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today...

Read more

Non-Regulatory

May 15, 2020

Affibody and Inmagene Announce Strategic Partnership to Develop ABY-035 – A Phase 2 Drug Candidate with Best-in-Class Potential for Auto-Immune Diseases

Solna, Sweden & Shanghai, China, May 15, 2020. Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced a strategic partnership to develop and commercialize ABY-035, a bispecific molecule targeting...

Read more